{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:08:11Z","timestamp":1773788891010,"version":"3.50.1"},"reference-count":199,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MEC-URO\/ 29043\/2017"],"award-info":[{"award-number":["PTDC\/MEC-URO\/ 29043\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/132751\/2017"],"award-info":[{"award-number":["SFRH\/BD\/132751\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Testicular germ cell tumors share a marked sensitivity to cisplatin, contributing to their overall good prognosis. However, a subset of patients develop resistance to platinum-based treatments, by still-elusive mechanisms, experiencing poor quality of life due to multiple (often ineffective) interventions and, eventually, dying from disease. Currently, there is a lack of defined treatment opportunities for these patients that tackle the mechanism(s) underlying the emergence of resistance. Herein, we aim to provide a multifaceted overview of cisplatin resistance in testicular germ cell tumors, from the clinical perspective, to the pathobiology (including mechanisms contributing to induction of the resistant phenotype), to experimental models available for studying this occurrence. We provide a systematic summary of pre-target, on-target, post-target, and off-target mechanisms putatively involved in cisplatin resistance, providing data from preclinical studies and from those attempting validation in clinical samples, including those exploring specific alterations as therapeutic targets, some of them included in ongoing clinical trials. We briefly discuss the specificities of resistance related to teratoma (differentiated) phenotype, including the phenomena of growing teratoma syndrome and development of somatic-type malignancy. Cisplatin resistance is most likely multifactorial, and a combination of therapeutic strategies will most likely produce the best clinical benefit.<\/jats:p>","DOI":"10.3390\/cancers12061601","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T11:00:56Z","timestamp":1592478056000},"page":"1601","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-1391","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Lobo","sequence":"first","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) &amp; Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) &amp; Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) &amp; Porto Comprehensive Cancer Center (P.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/ijc.32810","article-title":"Testicular cancer incidence predictions in Europe 2010\u20132035: A rising burden despite population ageing","volume":"147","author":"Znaor","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Fedorova, V.A., Kadyrova, R.A., Slita, A.V., Muryleva, A.A., Petrova, P.R., Kovalskaya, A.V., Lobov, A.N., Zileeva, Z.R., Tsypyshev, D.O., and Borisevich, S.S. (2019). Antiviral activity of amides and carboxamides of quinolizidine alkaloid (-)-cytisine against human influenza virus A (H1N1) and parainfluenza virus type 3. Nat. Prod. Res., 1\u20139.","DOI":"10.1080\/14786419.2019.1696791"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41568-019-0178-9","article-title":"Human germ cell tumours from a developmental perspective","volume":"19","author":"Oosterhuis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/his.12958","article-title":"Germ cell neoplasia in situ (GCNIS): Evolution of the current nomenclature for testicular pre-invasive germ cell malignancy","volume":"69","author":"Berney","year":"2016","journal-title":"Histopathology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.humpath.2018.07.016","article-title":"Testicular germ cell tumors: Revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists","volume":"82","author":"Lobo","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2174\/157339406777934681","article-title":"Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells","volume":"2","author":"Giuliano","year":"2006","journal-title":"Curr. Cancer Ther. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00184714","article-title":"The impact of the \u201ccisplatin era\u201d of treatment on survival in testicular cancer","volume":"9","author":"Moul","year":"1991","journal-title":"World J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11912-017-0572-y","article-title":"Current Management of Refractory Germ Cell Tumors and Future Directions","volume":"19","author":"Allen","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1159\/000488284","article-title":"Testicular Germ-Cell Tumours: A Descriptive Analysis of Clinical Characteristics at First Presentation","volume":"100","author":"Dieckmann","year":"2018","journal-title":"Urol. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1097\/PAS.0000000000001352","article-title":"Interobserver Agreement in Vascular Invasion Scoring and the Added Value of Immunohistochemistry for Vascular Markers to Predict Disease Relapse in Stage I Testicular Nonseminomas","volume":"43","author":"Lobo","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-18-3179","article-title":"Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms","volume":"25","author":"Mapes","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/iju.13597","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients","volume":"25","author":"Inoue","year":"2018","journal-title":"Int. J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/1055-9965.EPI-15-1153","article-title":"Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor","volume":"25","author":"Kvammen","year":"2016","journal-title":"Cancer Epidemiol. Prev. Biomark."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<848::AID-IJC29>3.0.CO;2-#","article-title":"Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG)","volume":"83","author":"Bokemeyer","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bakardjieva-Mihaylova, V., Skvarova Kramarzova, K., Slamova, M., Svaton, M., Rejlova, K., Zaliova, M., Dobiasova, A., Fiser, K., Stuchly, J., and Grega, M. (2019). Molecular Basis of Cisplatin Resistance in Testicular Germ Cell Tumors. Cancers (Basel), 11.","DOI":"10.3390\/cancers11091316"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/andr.12611","article-title":"Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: Past, present, and future considerations","volume":"7","author":"Oing","year":"2019","journal-title":"Andrology"},{"key":"ref_17","first-page":"580","article-title":"Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors","volume":"2","author":"Singh","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14737140.2018.1450630","article-title":"Therapeutic approaches for refractory germ cell cancer","volume":"18","author":"Oing","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2174\/1568009618666180102103959","article-title":"Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors-clinical Implications","volume":"18","author":"Kalavska","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11912-018-0730-x","article-title":"Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors","volume":"20","author":"Schmidtova","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00345-016-1898-z","article-title":"Platinum-refractory germ cell tumors: An update on current treatment options and developments","volume":"35","author":"Oing","year":"2017","journal-title":"World J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/andr.299","article-title":"Cisplatin resistance in germ cell tumours: Models and mechanisms","volume":"3","author":"Jacobsen","year":"2015","journal-title":"Andrology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1017\/erm.2013.13","article-title":"Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer","volume":"15","author":"Koster","year":"2013","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2009.26.8128","article-title":"Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy","volume":"28","author":"Lorch","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1097\/PAS.0000000000000844","article-title":"Reporting and Staging of Testicular Germ Cell Tumors: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations","volume":"41","author":"Verrill","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/annonc\/mdy217","article-title":"ESMO Consensus Conference on testicular germ cell cancer: Diagnosis, treatment and follow-up","volume":"29","author":"Honecker","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1111\/j.1365-2605.2011.01145.x","article-title":"Treatment of patients with relapsed and\/or cisplatin-refractory metastatic germ cell tumours: An update","volume":"34","author":"Koychev","year":"2011","journal-title":"Int. J. Androl."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdi228","article-title":"A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours","volume":"16","author":"Pico","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.2010.32.6678","article-title":"Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: Evidence from a large international database","volume":"29","author":"Lorch","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0022-5347(05)67365-X","article-title":"Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers","volume":"164","author":"Albers","year":"2000","journal-title":"J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1464-410X.2010.09631.x","article-title":"Histopathological and molecular features of late relapses in non-seminomas","volume":"107","author":"Mayer","year":"2011","journal-title":"BJU Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.21037\/atm.2019.07.01","article-title":"Testicular germ cell tumors: The changing role of the pathologist","volume":"7","author":"Ronchi","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1097\/PAS.0000000000001049","article-title":"Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations","volume":"42","author":"Verrill","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2008.18.8623","article-title":"Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors","volume":"27","author":"Honecker","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lobo, J., Rodrigues, A., Guimaraes, R., Cantante, M., Lopes, P., Mauricio, J., Oliveira, J., Jeronimo, C., and Henrique, R. (2019). Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1\/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers. Cancers (Basel), 11.","DOI":"10.3390\/cancers11101535"},{"key":"ref_36","first-page":"2758","article-title":"Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment","volume":"62","author":"Mayer","year":"2002","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/s41467-020-15768-x","article-title":"Genomic landscape of platinum resistant and sensitive testicular cancers","volume":"11","author":"Loveday","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1016\/j.celrep.2018.05.039","article-title":"Integrated Molecular Characterization of Testicular Germ Cell Tumors","volume":"23","author":"Shen","year":"2018","journal-title":"Cell Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3892\/ol.2015.3306","article-title":"Dimethyl sulfoxide induces chemotherapeutic resistance in the treatment of testicular embryonal carcinomas","volume":"10","author":"Kita","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lobo, J., Gillis, A.J.M., van den Berg, A., Dorssers, L.C.J., Belge, G., Dieckmann, K.P., Roest, H.P., van der Laan, L.J.W., Gietema, J., and Hamilton, R.J. (2019). Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data. Cells, 8.","DOI":"10.3390\/cells8121637"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-17-1898","article-title":"Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent","volume":"24","author":"Piulats","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Schmidtova, S., Kalavska, K., Gercakova, K., Cierna, Z., Miklikova, S., Smolkova, B., Buocikova, V., Miskovska, V., Durinikova, E., and Burikova, M. (2019). Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells. Cancers (Basel), 11.","DOI":"10.3390\/cancers11091224"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.0.CO;2-S","article-title":"Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines","volume":"81","author":"Burger","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1476-4598-10-52","article-title":"Micro-RNA expression in cisplatin resistant germ cell tumor cell lines","volume":"10","author":"Port","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/bjc.2012.481","article-title":"Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer","volume":"107","author":"Nitzsche","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/gcc.20520","article-title":"Further characterization of the first seminoma cell line TCam-2","volume":"47","author":"Stoop","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_47","first-page":"1211","article-title":"Establishment and characterization of a new human testicular germ cell tumor cell line (TCam-2)","volume":"84","author":"Mizuno","year":"1993","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"ref_48","unstructured":"Timmerman, D.M., Lobo, J., Gillis, A., Remmers, T., Schmidtova, S., Kalavska, K., Hulleman, E., Oing, C., Dorssers, L., and Ulbright, T. (2020). Sequential 12q- and 3p-amplification is associated with cisplatin resistance in male germ cell cancers, in preparation."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Schaffrath, J., Schmoll, H.J., Voigt, W., Muller, L.P., Muller-Tidow, C., and Mueller, T. (2017). Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0178930"},{"key":"ref_50","first-page":"5707","article-title":"cis-Diamminedichloroplatinum(ii) resistance in vitro and in vivo in human embryonal carcinoma cells","volume":"53","author":"Timmer","year":"1993","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000092324","article-title":"Loss of Oct-3\/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance","volume":"27","author":"Mueller","year":"2006","journal-title":"Tumor Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00280-009-0944-6","article-title":"The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines","volume":"64","author":"Perry","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00418-010-0710-1","article-title":"Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity","volume":"134","author":"Mueller","year":"2010","journal-title":"Histochem. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000320744","article-title":"Establishment of cisplatin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line","volume":"71","author":"Shibata","year":"2011","journal-title":"Gynecol. Obstet. Invest."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11295","DOI":"10.1073\/pnas.94.21.11295","article-title":"A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells","volume":"94","author":"Minucci","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","first-page":"4","article-title":"Cisplatin-Based Chemotherapy of Human Cancers","volume":"11","author":"Brown","year":"2019","journal-title":"J. Cancer Sci. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e1257","DOI":"10.1038\/cddis.2013.428","article-title":"Systems biology of cisplatin resistance: Past, present and future","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: A review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Chen, S.H., and Chang, J.Y. (2019). New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174136"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/annonc\/mdg242","article-title":"Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors","volume":"14","author":"Mayer","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","article-title":"Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals","volume":"99","author":"Ishida","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","first-page":"767","article-title":"Molecular determinants of treatment response in human germ cell tumors","volume":"9","author":"Mayer","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_64","first-page":"430939","article-title":"Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy","volume":"2010","author":"Chen","year":"2010","journal-title":"Met. Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/0959-8049(96)00033-0","article-title":"Sensitivity of testis tumour cells to chemotherapeutic drugs: Role of detoxifying pathways","volume":"32A","author":"Masters","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"ref_66","first-page":"1681","article-title":"Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line","volume":"275","author":"Koropatnick","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/(SICI)1097-0215(20000315)85:6<777::AID-IJC6>3.0.CO;2-D","article-title":"Role of metallothionein in cisplatin sensitivity of germ-cell tumours","volume":"85","author":"Meijer","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/andr.12651","article-title":"Germline genome protection: Implications for gamete quality and germ cell tumorigenesis","volume":"7","author":"Bloom","year":"2019","journal-title":"Andrology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1073\/pnas.1421365112","article-title":"Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells","volume":"112","author":"Srivastava","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1200\/JCO.2002.20.6.1551","article-title":"Role of P53 and MDM2 in treatment response of human germ cell tumors","volume":"20","author":"Kersemaekers","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1158\/1078-0432.CCR-08-2581","article-title":"Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma","volume":"15","author":"Michaud","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_72","first-page":"75","article-title":"Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy","volume":"25","author":"Ren","year":"2010","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1158\/1078-0432.CCR-06-2090","article-title":"Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity","volume":"13","author":"Zhang","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1111\/jcmm.14654","article-title":"Testis developmental related gene 1 regulates the chemosensitivity of seminoma TCam-2 cells to cisplatin via autophagy","volume":"23","author":"Peng","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/1078-0432.CCR-13-1131","article-title":"The PDGFRbeta-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors","volume":"20","author":"Juliachs","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_76","first-page":"3579","article-title":"The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts","volume":"58","author":"Vaisman","year":"1998","journal-title":"Cancer Res."},{"key":"ref_77","first-page":"4319","article-title":"Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors","volume":"25","author":"Olasz","year":"2005","journal-title":"Anticancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/his.13979","article-title":"Widening the spectrum of Lynch syndrome: First report of testicular seminoma attributable to MSH2 loss","volume":"76","author":"Lobo","year":"2020","journal-title":"Histopathology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13402-017-0326-8","article-title":"Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours","volume":"40","author":"Rudolph","year":"2017","journal-title":"Cell Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4161\/cbt.3.10.1135","article-title":"Mismatch repair gene expression and genetic instability in testicular germ cell tumor","volume":"3","author":"Velasco","year":"2004","journal-title":"Cancer Biol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/andr.12200","article-title":"Absence of microsatellite instability and BRAF (V600E) mutation in testicular germ cell tumors","volume":"4","author":"Carcano","year":"2016","journal-title":"Andrology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1568-7864(02)00150-7","article-title":"Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta","volume":"1","author":"Bassett","year":"2002","journal-title":"DNA Repair"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ijc.20134","article-title":"Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines","volume":"110","author":"Welsh","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0960-9822(99)80118-3","article-title":"Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours","volume":"9","author":"Koberle","year":"1999","journal-title":"Curr. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Cierna, Z., Miskovska, V., Roska, J., Jurkovicova, D., Pulzova, L.B., Sestakova, Z., Hurbanova, L., Machalekova, K., Chovanec, M., and Rejlekova, K. (2020). Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours. BMC Cancer, 20.","DOI":"10.1186\/s12885-019-6496-1"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/bjc.2013.303","article-title":"Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours","volume":"109","author":"Mendoza","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1073\/pnas.1615327114","article-title":"Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin hypersensitivity","volume":"114","author":"Awuah","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/mc.20418","article-title":"Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation","volume":"47","author":"Koberle","year":"2008","journal-title":"Mol. Carcinog."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/01.LAB.0000090221.95883.41","article-title":"Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors","volume":"83","author":"Honecker","year":"2003","journal-title":"Lab. Investig."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0006-2952(96)00549-7","article-title":"DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction","volume":"52","author":"Koberle","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"ref_91","first-page":"2220","article-title":"Altered expression of Ape1\/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation","volume":"61","author":"Robertson","year":"2001","journal-title":"Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Cavallo, F., Graziani, G., Antinozzi, C., Feldman, D.R., Houldsworth, J., Bosl, G.J., Chaganti, R.S., Moynahan, M.E., Jasin, M., and Barchi, M. (2012). Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0051563"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/jclinpath-2012-201088","article-title":"PARP expression in germ cell tumours","volume":"66","author":"Mego","year":"2013","journal-title":"J. Clin. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","article-title":"Mutant p53 as a guardian of the cancer cell","volume":"26","author":"Mantovani","year":"2019","journal-title":"Cell Death Differ."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1387\/ijdb.130135mb","article-title":"Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors","volume":"57","author":"Cavallo","year":"2013","journal-title":"Int. J. Dev. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/mc.2940120303","article-title":"The p53 and mdm-2 genes in human testicular germ-cell tumors","volume":"12","author":"Riou","year":"1995","journal-title":"Mol. Carcinog."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2605.2007.00772.x","article-title":"DNA damage response in human testes and testicular germ cell tumours: Biology and implications for therapy","volume":"30","author":"Bartkova","year":"2007","journal-title":"Int. J. Androl."},{"key":"ref_99","first-page":"1221","article-title":"Germ cell tumors of the testis overexpress wild-type p53","volume":"149","author":"Guillou","year":"1996","journal-title":"Am. J. Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Gutekunst, M., Oren, M., Weilbacher, A., Dengler, M.A., Markwardt, C., Thomale, J., Aulitzky, W.E., and van der Kuip, H. (2011). p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019198"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/0008-5472.CAN-12-2876","article-title":"Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4","volume":"73","author":"Gutekunst","year":"2013","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1038\/sj.onc.1201770","article-title":"Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation","volume":"16","author":"Houldsworth","year":"1998","journal-title":"Oncogene"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2016.68.7798","article-title":"Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors","volume":"34","author":"Bagrodia","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.4161\/cc.22803","article-title":"Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent","volume":"11","author":"Koster","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"26495","DOI":"10.1074\/jbc.M112.376319","article-title":"Transcription factors Sp1 and p73 control the expression of the proapoptotic protein NOXA in the response of testicular embryonal carcinoma cells to cisplatin","volume":"287","author":"Grande","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1073\/pnas.1016201108","article-title":"Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes","volume":"108","author":"Beyer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.cell.2006.02.037","article-title":"A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors","volume":"124","author":"Voorhoeve","year":"2006","journal-title":"Cell"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.eururo.2009.06.014","article-title":"Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours","volume":"57","author":"Bauer","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/cddis.2011.33","article-title":"Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas\/FasL pathway","volume":"2","author":"Koster","year":"2011","journal-title":"Cell Death Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.4161\/cc.9.7.11255","article-title":"p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors","volume":"9","author":"Li","year":"2010","journal-title":"Cell Cycle"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s12094-012-0823-1","article-title":"Biological markers of cisplatin resistance in advanced testicular germ cell tumours","volume":"14","author":"Duran","year":"2012","journal-title":"Clin. Transl. Oncol."},{"key":"ref_112","first-page":"1641","article-title":"Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment","volume":"28","author":"Mandoky","year":"2008","journal-title":"Anticancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Lobo, J., Alzamora, M.A., Guimaraes, R., Cantante, M., Lopes, P., Braga, I., Mauricio, J., Jeronimo, C., and Henrique, R. (2020). p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome. Andrology.","DOI":"10.1111\/andr.12814"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/jmcb\/mjz007","article-title":"The long and the short of it: The MDM4 tail so far","volume":"11","author":"Haupt","year":"2019","journal-title":"J. Mol. Cell Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1200\/JCO.2017.35.6_suppl.417","article-title":"Molecular dissection of primary mediastinal germ cell tumors","volume":"35","author":"Nappi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1002\/cam4.2195","article-title":"Extragonadal germ cell tumors: Not just a matter of location. A review about clinical, molecular and pathological features","volume":"8","author":"Ronchi","year":"2019","journal-title":"Cancer Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"a000687","DOI":"10.1101\/mcs.a000687","article-title":"A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia","volume":"2","author":"Lu","year":"2016","journal-title":"Mol. Case Stud."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/CAD.0000000000000666","article-title":"B-cell lymphoma 2 ovarian killer suppresses testicular cancer cell malignant behavior, but plays a role in platinum resistance","volume":"29","author":"Chu","year":"2018","journal-title":"Anticancer Drugs"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1365-2559.2005.02118.x","article-title":"Overexpression of anti-apoptotic Mcl-1 in testicular germ cell tumours","volume":"46","author":"Sano","year":"2005","journal-title":"Histopathology"},{"key":"ref_120","first-page":"1834","article-title":"Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio","volume":"56","author":"Chresta","year":"1996","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/bjc.1998.257","article-title":"Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines","volume":"77","author":"Burger","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1464-410x.2001.02151.x","article-title":"P53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours","volume":"87","author":"Baltaci","year":"2001","journal-title":"BJU Int."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.2353\/ajpath.2010.090780","article-title":"The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers","volume":"176","author":"Noel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2217\/epi-2016-0081","article-title":"The epigenetics of testicular germ cell tumors: Looking for novel disease biomarkers","volume":"9","author":"Costa","year":"2017","journal-title":"Epigenomics"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1476-4598-3-16","article-title":"Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors","volume":"3","author":"Koul","year":"2004","journal-title":"Mol. Cancer"},{"key":"ref_126","first-page":"363","article-title":"Association between RASSF1A Promoter Methylation and Testicular Germ Cell Tumor: A Meta-analysis and a Cohort Study","volume":"14","author":"Markulin","year":"2017","journal-title":"Cancer Genom. Proteom."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.juro.2009.02.106","article-title":"CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer","volume":"182","author":"Ellinger","year":"2009","journal-title":"J. Urol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"50608","DOI":"10.18632\/oncotarget.11167","article-title":"MGMT and CALCA promoter methylation are associated with poor prognosis in testicular germ cell tumor patients","volume":"8","author":"Martinelli","year":"2017","journal-title":"Oncotarget"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"9360","DOI":"10.1158\/0008-5472.CAN-09-1490","article-title":"High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors","volume":"69","author":"Beyrouthy","year":"2009","journal-title":"Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/bjc.2014.128","article-title":"Aza-deoxycytidine induces apoptosis or differentiation via DNMT3B and targets embryonal carcinoma cells but not their differentiated derivatives","volume":"110","author":"Wongtrakoongate","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Biswal, B.K., Beyrouthy, M.J., Hever-Jardine, M.P., Armstrong, D., Tomlinson, C.R., Christensen, B.C., Marsit, C.J., and Spinella, M.J. (2012). Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0053003"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/path.2725","article-title":"Global DNA methylation in fetal human germ cells and germ cell tumours: Association with differentiation and cisplatin resistance","volume":"221","author":"Wermann","year":"2010","journal-title":"J. Pathol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Singh, R., Fazal, Z., Corbet, A.K., Bikorimana, E., Rodriguez, J.C., Khan, E.M., Shahid, K., Freemantle, S.J., and Spinella, M.J. (2019). Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors. Cancers (Basel), 11.","DOI":"10.3390\/cancers11060796"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/neuonc\/nox186","article-title":"Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors","volume":"20","author":"Hsieh","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/jcp.24394","article-title":"MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death","volume":"228","author":"Liu","year":"2013","journal-title":"J. Cell Physiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1101\/gad.298984.117","article-title":"The interplay between epigenetic changes and the p53 protein in stem cells","volume":"31","author":"Levine","year":"2017","journal-title":"Genes Dev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature05287","article-title":"Repression of p53 activity by Smyd2-mediated methylation","volume":"444","author":"Huang","year":"2006","journal-title":"Nature"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.molcel.2007.07.012","article-title":"Modulation of p53 function by SET8-mediated methylation at lysine 382","volume":"27","author":"Shi","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"9822","DOI":"10.1073\/pnas.1610387113","article-title":"Lysine methylation represses p53 activity in teratocarcinoma cancer cells","volume":"113","author":"Zhu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41416-019-0381-1","article-title":"Molecular heterogeneity and early metastatic clone selection in testicular germ cell cancer development","volume":"120","author":"Dorssers","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Barrett, M.T., Lenkiewicz, E., Malasi, S., Stanton, M., Slack, J., Andrews, P., Pagliaro, L., and Bryce, A.H. (2019). Clonal analyses of refractory testicular germ cell tumors. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0213815"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.euf.2018.07.013","article-title":"Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy","volume":"6","author":"Necchi","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1067\/j.cpradiol.2012.02.001","article-title":"Teratomas: A multimodality review","volume":"41","author":"Peterson","year":"2012","journal-title":"Curr. Probl. Diagn. Radiol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12253-016-0120-3","article-title":"More Cases of Benign Testicular Teratomas are Detected in Adults than in Children. A Clinicopathological Study of 543 Testicular Germ Cell Tumor Cases","volume":"23","author":"David","year":"2017","journal-title":"Pathol. Oncol. Res."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Anheuser, P., Kranz, J., Stolle, E., Hoflmayer, D., Buscheck, F., Muhlstadt, S., Lock, G., and Dieckmann, K.P. (2019). Testicular epidermoid cysts: A reevaluation. BMC Urol., 19.","DOI":"10.1186\/s12894-019-0477-1"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/j.1464-410X.2009.08855.x","article-title":"Molecular events in germ cell tumours: Linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin","volume":"104","author":"Korkola","year":"2009","journal-title":"BJU Int."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-4608(96)00284-1","article-title":"Cytogenetics of primary testicular nonseminoma, residual mature teratoma, and growing teratoma lesion in individual patients","volume":"96","author":"Sleijfer","year":"1997","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/annonc\/mdt493","article-title":"What are the indications for postchemotherapy retroperitoneal lymph node dissection?","volume":"25","author":"Einhorn","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/BF00185671","article-title":"Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: Outcome analysis","volume":"12","author":"Donohue","year":"1994","journal-title":"World J. Urol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41585-020-0296-x","article-title":"Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours","volume":"17","author":"Almstrup","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/bjc.2016.187","article-title":"The cancer\/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas","volume":"115","author":"Nettersheim","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/gcc.20918","article-title":"The seminoma cell line TCam-2 is sensitive to HDAC inhibitor depsipeptide but tolerates various other chemotherapeutic drugs and loss of NANOG expression","volume":"50","author":"Nettersheim","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-05-0153","article-title":"Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development","volume":"65","author":"Skotheim","year":"2005","journal-title":"Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jprot.2013.11.010","article-title":"Proteome analysis of the effects of all-trans retinoic acid on human germ cell tumor cell lines","volume":"96","author":"Honecker","year":"2014","journal-title":"J. Proteom."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature20596","article-title":"Genomic evolution and chemoresistance in germ-cell tumours","volume":"540","author":"Zack","year":"2016","journal-title":"Nature"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1172\/JCI41939","article-title":"Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer","volume":"120","author":"Koster","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_159","first-page":"2244","article-title":"POU5F1 (OCT3\/4) identifies cells with pluripotent potential in human germ cell tumors","volume":"63","author":"Looijenga","year":"2003","journal-title":"Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/1097-0142(19950815)76:4<680::AID-CNCR2820760423>3.0.CO;2-9","article-title":"All-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial","volume":"76","author":"Moasser","year":"1995","journal-title":"Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.celrep.2017.10.078","article-title":"Chemotherapy-Induced Depletion of OCT4-Positive Cancer Stem Cells in a Mouse Model of Malignant Testicular Cancer","volume":"21","author":"Pierpont","year":"2017","journal-title":"Cell Rep."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"529.e23","DOI":"10.1016\/j.urolonc.2018.09.012","article-title":"Diagnosis and management of the growing teratoma syndrome: A single-center experience and review of the literature","volume":"36","author":"Paffenholz","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/1097-0142(19821015)50:8<1629::AID-CNCR2820500828>3.0.CO;2-1","article-title":"The growing teratoma syndrome","volume":"50","author":"Logothetis","year":"1982","journal-title":"Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ucl.2019.04.008","article-title":"Management, Treatment, and Molecular Background of the Growing Teratoma Syndrome","volume":"46","author":"Hiester","year":"2019","journal-title":"Urol. Clin. North Am."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12032-018-1215-3","article-title":"Testicular teratomas: A growing problem?","volume":"35","author":"Michalski","year":"2018","journal-title":"Med. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000495802","article-title":"Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience","volume":"42","author":"Scheckel","year":"2019","journal-title":"Oncol. Res. Treat."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1464-410X.2010.09705.x","article-title":"Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: A single-institution case series and new proposal","volume":"107","author":"Necchi","year":"2011","journal-title":"BJU Int."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.juro.2015.12.082","article-title":"Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration","volume":"196","author":"Giannatempo","year":"2016","journal-title":"J. Urol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1066896910390680","article-title":"Teratoma with somatic-type malignant components in germ cell tumors of the testis: A clinicopathologic analysis of 40 cases with outcome correlation","volume":"19","author":"Colecchia","year":"2011","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Dashti, N.K., and Jimenez, R.E. (2017). Somatic-type malignancy in germ cell tumors. Pathology and Biology of Human Germ Cell Tumors, Springer.","DOI":"10.1007\/978-3-662-53775-6_12"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2147\/OTT.S192111","article-title":"Postchemotherapy sarcoma as a somatic-type malignancy derived from the gonadal yolk sac tumor in a patient with 46, XY pure gonadal dysgenesis","volume":"12","author":"Zong","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/MOU.0000000000000642","article-title":"Genetics of testicular germ cell tumors","volume":"29","author":"Singla","year":"2019","journal-title":"Curr. Opin. Urol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3718165","DOI":"10.1155\/2018\/3718165","article-title":"Immune-Related Concepts in Biology and Treatment of Germ-Cell Tumors","volume":"2018","author":"Chovanec","year":"2018","journal-title":"Adv. Urol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/andr.12656","article-title":"Immune mechanisms and possible immune therapy in testicular germ cell tumours","volume":"7","author":"Chovanec","year":"2019","journal-title":"Andrology"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/bjc.2015.244","article-title":"Frequent PD-L1 expression in testicular germ cell tumors","volume":"113","author":"Fankhauser","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/annonc\/mdv574","article-title":"Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors","volume":"27","author":"Cierna","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"21794","DOI":"10.18632\/oncotarget.15585","article-title":"Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors","volume":"8","author":"Chovanec","year":"2017","journal-title":"Oncotarget"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: A Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2018.09.010","article-title":"An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis","volume":"75","author":"Necchi","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s10637-019-00805-4","article-title":"Phase II study of avelumab in multiple relapsed\/refractory germ cell cancer","volume":"37","author":"Mego","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/MOU.0000000000000531","article-title":"Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer","volume":"28","author":"Oing","year":"2018","journal-title":"Curr. Opin. Urol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdw146","article-title":"Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors","volume":"27","author":"Zschabitz","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2217\/fon-2018-0571","article-title":"Immunotherapy: Last bullet in platinum refractory germ cell testicular cancer","volume":"15","author":"Semaan","year":"2019","journal-title":"Future Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Oing, C., Verem, I., Mansour, W.Y., Bokemeyer, C., Dyshlovoy, S., and Honecker, F. (2018). 5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010021"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.18632\/oncotarget.13811","article-title":"Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine","volume":"8","author":"Albany","year":"2017","journal-title":"Oncotarget"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/sj.bjc.6604932","article-title":"Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo","volume":"100","author":"Steele","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF00874155","article-title":"5-Azacytidine (NSC 102816) in refractory germ cell tumors","volume":"11","author":"Roth","year":"1993","journal-title":"Investig. New Drugs"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1078-0432.CCR-17-3055","article-title":"A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses","volume":"24","author":"Matei","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/cdd.2015.68","article-title":"Comprehensive identification of genes driven by ERV9-LTRs reveals TNFRSF10B as a re-activatable mediator of testicular cancer cell death","volume":"23","author":"Beyer","year":"2016","journal-title":"Cell Death Differ."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"74931","DOI":"10.18632\/oncotarget.11647","article-title":"A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment","volume":"7","author":"Nettersheim","year":"2016","journal-title":"Oncotarget"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/jcmm.13059","article-title":"The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo","volume":"21","author":"Jostes","year":"2017","journal-title":"J. Cell Mol. Med."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Kurz, L., Miklyaeva, A., Skowron, M.A., Overbeck, N., Poschmann, G., Becker, T., Eul, K., Kurz, T., Schonberger, S., and Calaminus, G. (2020). ARID1A Regulates Transcription and the Epigenetic Landscape via POLE and DMAP1 while ARID1A Deficiency or Pharmacological Inhibition Sensitizes Germ Cell Tumor Cells to ATR Inhibition. Cancers (Basel), 12.","DOI":"10.3390\/cancers12040905"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Lobo, J., Jeronimo, C., and Henrique, R. (2020). Targeting the Immune system and Epigenetic Landscape of Urological Tumors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030829"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00432-018-2752-z","article-title":"Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: Results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group","volume":"145","author":"Fenner","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00432-019-03071-2","article-title":"Treatment of refractory germ-cell tumours with single-agent cabazitaxel: A German Testicular Cancer Study Group case series","volume":"146","author":"Oing","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0959-8049(96)00521-7","article-title":"Inhibition of telomerase activity by cisplatin in human testicular cancer cells","volume":"33","author":"Burger","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0959-8049(01)00406-3","article-title":"Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines","volume":"38","author":"Cressey","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Skowron, M.A., Vermeulen, M., Winkelhausen, A., Becker, T.K., Bremmer, F., Petzsch, P., Schonberger, S., Calaminus, G., Kohrer, K., and Albers, P. (2020). CDK4\/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms. Br. J. Cancer.","DOI":"10.1038\/s41416-020-0891-x"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1158\/1078-0432.CCR-08-2170","article-title":"Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors","volume":"15","author":"Piulats","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1601\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:39:56Z","timestamp":1760175596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":199,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cancers12061601"],"URL":"https:\/\/doi.org\/10.3390\/cancers12061601","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]}}}